Board of Directors
News & Media
Investor and Media Contact
Systemic Lupus Erythematosus
Appendix 4E and Financial Report for year ended 30 June 2017
Invion announces strategic transaction
Appendix 4C – June 2017 Quarter
Invion is a life sciences company focussed on the development of treatments for major opportunities in inflammatory diseases. Invion is an ASX listed company (ASX:IVX), with operations in Brisbane, Australia and Delaware, USA.
Invion has entered into an exclusive commercialisation and distribution agreement to NGPDT technologies for the treatment of cancers, as well as a global R&D Agreement to conduct clinical trials initially targeting prostate cancer.
Invion Limited – Targeting Inflammation